Aytu Biopharma (AYTU) Q4 2026 earnings summary

Executive summary

• Q4 2026 net revenue rose 6.4% year-over-year to $16.1 million, driven by EXXUA's commercial launch and strong prescription growth.

• EXXUA, the first FDA-approved selective serotonin 5-HT1A receptor agonist for MDD, is gaining traction with expanding physician and patient adoption.

• Full year 2026 net revenue declined 13.3% to $57.6 million, reflecting portfolio reprioritization and generic competition.

• The company returned to positive adjusted EBITDA in Q4, emphasizing disciplined commercial investment and cash preservation.

• Cash and cash equivalents stood at $26.3 million as of June 30, 2026.

Financial highlights

• Q4 2026 net revenue was $16.1M, up from $12.4M in Q3; full-year revenue reached $57.6M.

• EXXUA contributed $3.9M in Q4 revenue, up from $2.4M in Q3; full year EXXUA revenue was $6.6M.

• ADHD portfolio delivered $10.4M in Q4; pediatric portfolio contributed $1.8M.

• Q4 gross profit was $10.4M (64.6% margin); adjusted EBITDA was $0.5M; net loss was approximately break-even.

• Stockholders’ equity at June 30, 2026: $35.3M, up from $19M a year earlier.

Outlook and guidance

• Fiscal 2027 operating expenses expected at $49M–$54M GAAP ($45M–$49M cash-based), with increased sales and marketing for EXXUA.

• Gross margin projected to improve through FY27, reaching 66–67% by Q4.

• Positive adjusted EBITDA and improved cash flow anticipated in the second half of FY27.

• Management expects continued EXXUA momentum and aims for sustained growth and more consistent positive Adjusted EBITDA as fiscal 2027 progresses.

• Focus remains on disciplined commercial execution and leveraging legacy portfolio profitability to support EXXUA investment.